BACKGROUND: Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis. DESIGN AND METHODS: We reviewed 56 patients with light chain amyloidosis who had cIg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution. RESULTS: Seventy percent of patients had abnormal cIg-FISH, with the most common abnormalities being IgH translocations [48%]--including t(11;14) [39%], and t(14;16) [2%]--and del13/del13q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(11;14) had the lowest levels of clonal plasma cells, and those with del13 had the highest. The risk of death for patients harboring the t(11;14) translocation was 2.1 (CI 1.04-6.4), which on multivariate analysis was independent of therapy. CONCLUSIONS: Although preliminary, our data would suggest that cIg-FISH testing is important in patients with light chain amyloidosis and that t(11;14) is an adverse prognostic factor in these patients.
BACKGROUND: Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis. DESIGN AND METHODS: We reviewed 56 patients with light chain amyloidosis who had cIg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution. RESULTS: Seventy percent of patients had abnormal cIg-FISH, with the most common abnormalities being IgH translocations [48%]--including t(11;14) [39%], and t(14;16) [2%]--and del13/del13q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(11;14) had the lowest levels of clonal plasma cells, and those with del13 had the highest. The risk of death for patients harboring the t(11;14) translocation was 2.1 (CI 1.04-6.4), which on multivariate analysis was independent of therapy. CONCLUSIONS: Although preliminary, our data would suggest that cIg-FISH testing is important in patients with light chain amyloidosis and that t(11;14) is an adverse prognostic factor in these patients.
Authors: N Zojer; R Königsberg; J Ackermann; E Fritz; S Dallinger; E Krömer; H Kaufmann; L Riedl; H Gisslinger; S Schreiber; R Heinz; H Ludwig; H Huber; J Drach Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: S R Hayman; R J Bailey; S M Jalal; G J Ahmann; A Dispenzieri; M A Gertz; P R Greipp; R A Kyle; M Q Lacy; S V Rajkumar; T E Witzig; J A Lust; R Fonseca Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: V Perfetti; A M Coluccia; D Intini; U Malgeri; M C Vignarelli; S Casarini; G Merlini; A Neri Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: Christine J Harrison; Helen Mazzullo; Fiona M Ross; Kan L Cheung; Gareth Gerrard; Louise Harewood; Atul Mehta; Helen J Lachmann; Philip N Hawkins; Kim H Orchard Journal: Br J Haematol Date: 2002-05 Impact factor: 6.998
Authors: Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: R Fonseca; G J Ahmann; S M Jalal; G W Dewald; D R Larson; T M Therneau; M A Gertz; R A Kyle; P R Greipp Journal: Br J Haematol Date: 1998-12 Impact factor: 6.998
Authors: Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: Blood Date: 2010-08-26 Impact factor: 22.113
Authors: Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin Journal: Amyloid Date: 2011-08-11 Impact factor: 7.141
Authors: E Muchtar; A Dispenzieri; S K Kumar; R P Ketterling; D Dingli; M Q Lacy; F K Buadi; S R Hayman; P Kapoor; N Leung; R Chakraborty; W Gonsalves; R Warsame; T V Kourelis; S Russell; J A Lust; Y Lin; R S Go; S Zeldenrust; R A Kyle; S V Rajkumar; M A Gertz Journal: Leukemia Date: 2016-12-01 Impact factor: 11.528